Lung Cancer Flashcards
(69 cards)
1
Q
How common is lung cancer?
A
- 3rd most common (UK)
- leading cause of death
2
Q
Who is most likely to have lung cancer?
A
- 75-90yrs old
- males
- low socioeconomic status
- smoking
3
Q
What are the causes of lung cancer?
A
- smoking
- passive smoking
- asbestos (x2)
- radon
- indoor cooking fumes
- chronic lung disease (COPD, Fibrosis)
- Immunodeficiency
- genetics/family history
4
Q
What are the 4 different types of lung cancer?
A
- squamous cell carcinoma
- adenocarcinoma
- large cell lung cancer
- small cell lung cancer
5
Q
What is squamous cell carcinoma?
A
- 30% of cases
- originates @ bronchial epithelium
- centrally located
6
Q
What is adenocarcinoma?
A
- 40% of cases
- possible link to tar cigarettes
- originates from mucus producing glandular tissue
- located peripherally
7
Q
What is large cell lung carcinoma?
A
- 15%
- heterogenous group
- undifferentiated
8
Q
What is small cell lung cancer?
A
- 15%
- originates at pulmonary neuroendocrine cells
- highly malignant
9
Q
What cancers make up Non-Small Cell Lung Cancer?
A
- squamous cell carcinoma
- adenocarcinoma
- large cell lung cancer
10
Q
What histology can be seen in early lung cancer development?
A
hyperplasia, followed by squamous metaplasia
11
Q
What histology can be seen in intermediate lung cell cancer development?
A
dysplasia
12
Q
What histology can be seen in late lung cell cancer development?
A
carcinoma in situ followed by an invasive carcinoma
13
Q
What is metaplasia?
A
reversible change in which one adult cell type replaced by another adult cell type; adaptive
14
Q
What is dysplasia?
A
abnormal pattern of growth in which some of the cellular and architectural features of malignancy are present; pre-invasive stage with INTACT basement membrane
15
Q
What is an oncogene?
A
genetic mutations that predisposes someone to a particular cancer, important to inform treatment/prevention
16
Q
What is impact of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase mutation?
A
- 15-30% adenocarcinoma seen in: - women - asian ethnicity - never-smokers
17
Q
What is the impact of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase mutation?
A
- 2-7% of non-small cell lung cancer
seen in: - youth
- never-smokers
18
Q
What is the impact of a mutation in c-ROS Oncogene 1 (ROS-1) Receptor Tyrosine Kinase?
A
- 1-2% of non-small cell lung cancer
seen in: - youth
- never-smokers
19
Q
What is the impact of a mutation in BRAF (downstream cell-cycle signalling mediator)?
A
- 1-3% of non-small cell lung cancer
seen in: - smokers
20
Q
What are the key symptoms of lung cancer?
A
- cough
- weight loss
- breathlessness
- fatigue
- chest pain
- haemoptysis
OFTEN ASYMPTOMATIC
21
Q
What are the features of advanced/metastatic disease?
A
neurological features - focal weakness - seizures - spinal cord compression bone pain paraneoplastic syndromes: - clubbing - hypercalcaemia - hyponatraemia - cushing's
22
Q
What are the common signs seen with lung cancer?
A
- clubbing
- cachexia
- Horner’s syndrome
- Pemberton’s sign
23
Q
What is Pemberton’s sign?
A
Superior vena cava obstruction
24
Q
What is Horner’s syndrome?
A
- contracted pupil
- drooping upper eyelid
- loss of sweating on one side of the face
25
What is the most useful form of imaging to see occult metastases?
PET scan
26
What types of imaging are used to diagnose lung cancer?
- Chest x-ray
- Staging CT (chest+abdomen)
- PET scan
27
When should a bronchoscopy be used in lung cancer?
- tumours of the central airway
| - no need for tissue staging
28
What is the method of a primary biopsy?
# Choose based on:
- accessibility
- availability
- impact on staging
29
What is the aim of an Endobronchial US and Transbronchial-needle aspiration of the mediastinal lymph nodes?
stage mediastinum +/- achieve tissue diagnosis
30
Why would you do a CT-guided lung biopsy?
to access peripheral lung tumours
31
What does T1-4 represent in staging?
tumour size and location
32
What does N0-3 represent in staging?
lymph node involvement - mediastinum and beyond
33
What does M0-1c represent in staging?
metastases and the number of them
34
What are the determinants of treatment?
- patient fitness
- cancer histology
- cancer stage
- patient preference
- health service factors
35
What are the different classifications in the WHO performance status?
0 - Asymptomatic
1 - Symptomatic, completely ambulatory
2 - symptomatic, <50% in bed during the day
3 - symptomatic, >50% in bed, not bedbound
4 - bedbound
5 - death
36
Which WHO performance statuses is radical treatment restricted to?
PS 0-2
37
What should also be taken into account with the WHO performance status?
- comorbidity
| - lung function
38
What is the standard of care for early stage lung cancer?
- surgical resection
| - radiotherapy with curative intent
39
What is the most common surgical resection done in lung cancer?
- lobectomy
| (+/-) lymphandectomy
40
What is the surgical resection done if the cancer is stage I (= 3cm)?
sublobar resection
41
What is a wedge resection?
removal of a small part of the lung
| tumour + a margin of healthy tissue
42
What is a segmental resection?
removing a large part of the lung, but NOT an entire lobe
43
What is a lobectomy?
removal of an entire lobe of the lung
44
What is a pneumonectomy?
removal of an entire lung.
45
What is an alternative to surgery for early stage lung cancer due to comorbidities?
radical radiotherapy
46
What is Radical Radiotherapy?
Stereotactic Ablative Body Radiotherapy (SABR)
- high precision targeting
- multiple, convergent beams
47
What is the first line treatment for metastatic non-small cell lung cancer with mutation?
Oncogene-directed treatments
48
What is treatment of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase mutation?
- erlotinib
- gefitinib
- afatinib
- dacomitinib
- osimertinib
49
What is the treatment of Anaplastic Lymphoma Kinase (ALK) Tyrosine Kinase mutation?
- crizotinib
- ceritinib
- alectinib
- brigatinib
- lorlatinib
50
What is the treatment of a mutation in c-ROS Oncogene 1 (ROS-1) Receptor Tyrosine Kinase?
- cirzotinib
| - entrectinib
51
What is the efficacy of oncogene-directed treatment?
- increase progression-free survival
| - no increase in overall survival when compared to chemotherapy
52
What are the side effects on oncogene-directed treatment?
- well tolerated (tablets)
- rash
- diarrhoea
UNCOMMON:
- pneumonitis
53
How does immunotherapy to treat lung cancer work?
blocks PD-L1/PD-1 to allow T-cell killing of the cell
54
What is the first line treatment for NSCLC with NO mutation (PDL1>50%)?
immunotherapy
- prembrolizumab
- atezolizumab
- nivolumab
55
What is the efficacy of immunotherapy?
greater progression-free survival and overall survival in comparison to chemotherapy
56
What are the side effects of immunotherapy?
- well tolerated
| - (10-15%) immune-related side effects (thyroid, skin, bowel, lung and liver)
57
What is the first line treatment for metastatic NSCLC with NO mutation and PDL<50%?
cytotoxic chemotherapy
| + immunotherapy
58
What is cytotoxic chemotherapy?
- targets rapidly dividing cells
- long established
- paltinum-based regimens (carboplatin, cisplatin, paclitaxel, premetrexed)
59
What is the efficacy of cytotoxic chemotherapy?
alone:
modest survival improvements
w/ immunotherapy (pembrolizumab):
significantly better
60
What are the side effects of cytotoxic chemotherapy?
- fatigue
- nausea
- bone marrow suppression
- nephrotoxicity
61
What is palliative and supportive care?
- symptom control
- psychological support
- education
- practical and financial support
- end-of-life planning
62
When is palliative care given?
all patients with advanced stage disease
63
What is key for successful palliative care?
lung cancer specialist nurses
64
What is the impact of palliative care (+standard oncology care)?
- improved quality of life
- lower depression scores
- increased survival (2.5 months)
65
What is the expected treatment of locally advanced treatment (involving thoracic lymph nodes)?
- surgery and adjuvant chemotherapy
| - radiotherapy and chemotherapy (+/- immunotherapy)
66
What is the treatment for metastatic lung disease with a targetable mutation?
- tyrosine kinase inhibitor
| - palliative care
67
What is the treatment for metastatic lung disease with NO mutation, PDL-1 positive (>50%)?
- immunotherapy, ALONE
| - palliative care
68
What is the treatment for metastatic lung disease with NO mutation, PDL-1 negative (<50%)?
- immunotherapy + chemotherapy
| - palliative care
69
What is the prognosis of lung cancer?
only 10% live longer than 10 years
